Health tech, AI, big data and real world data are going to change the R&D and business models of the Life Sciences industry
Rigid regulation, demanding clinical trials and licensing processes may have held back the digitalization of life sciences sector. However, the health tech, AI, big data and especially real world data are going to take over and change the R&D and business models of the industry.
We regularly serve world leading pharmaceutical and biotechnology companies, producers and distributors of medical devices, hospitals and other healthcare providers in all their strategic legal needs. We also have a significant experience in life sciences and healthcare related competition issues, including parallel imports, abuse of dominant position, competition filings, dawn raids, compliance programs, as well as public procurement.
Our services include all legal aspects of pharmaceuticals distribution and marketing in Finland including regulative and IPR issues as well as matters related to the development of pharmaceuticals, clinical trials, marketing authorisations complex pricing- and reinburcement issues, and biosimilars. We also assist our clients in the issues related to the life-line of the pharmaceutical and medical device products. We also deal regularly with the Pharma Industry Finland’s Inspection Boards and Supervisory Commission as well as the Finnish Medicines Agency (Fimea).
M&A transactions in the pharmaceuticals sector require significant industry knowledge. Our specialized industry knowledge within this sector is highly-ranked.
Main contact: Partner Juli Mansnérus
